Changeflow GovPing Pharma & Drug Safety Clinical trial NCT07515456, theophylline vs sum...
Routine Notice Added Final

Clinical trial NCT07515456, theophylline vs sumatriptan, gabapentin

Favicon for clinicaltrials.gov ClinicalTrials.gov
Detected April 7th, 2026
Email

Summary

NIH National Library of Medicine registered clinical trial NCT07515456 on ClinicalTrials.gov. The trial is a Phase 2/3 randomized study evaluating theophylline compared to sumatriptan and gabapentin for an undisclosed condition, enrolling approximately 60 participants aged 18-65.

What changed

A new clinical trial registration for NCT07515456 was posted to the ClinicalTrials.gov public registry. The trial will study theophylline versus sumatriptan and gabapentin as comparators in a randomized design.

For sponsors, clinical investigators, and pharmaceutical companies, this registry entry provides visibility into ongoing comparative effectiveness research for these generic pharmaceutical compounds. No immediate compliance actions are required; however, organizations conducting similar research should be aware of this competitive trial.

What to do next

  1. Monitor ClinicalTrials.gov for updated enrollment status and results

Source document (simplified)

Show glossary

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
NLM/NIH
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07515456

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Drug research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Pharmaceuticals Public Health

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ClinicalTrials.gov publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.